检索结果-南通市图书馆

Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B

World Journal of Gastroenterology 2012年第43期18卷 6277-6283页

作者： Myeong Jun Song Do Seon Song Hee Yeon Kim Sun Hong Yoo Si Hyun Bae Jong Young Choi Seung Kew Yoon Yong-Han Paik June Sung Lee Hyun Woong Lee Hyung Joon Kim Departments of Internal Medicine College of Medicine The Catholic University of Korea Seoul 137-040 South Korea Departments of Internal Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul 135-710 South Korea Departments of Internal Medicine College of Medicine Inje University Ilsan Paik Hospital of The Korea Goyang-si 411-706 South Korea Departments of Internal Medicine College of Medicine The Chung-Ang University of Korea Seoul 156-755 South Korea

AIM:To evaluate the durability in hepatitis B e antigen (HBeAg) positive chronic hepatitis B patients who discontinued antiviral treatment. METHODS:A total of 48 HBeAg positive chronic hepatitis B patients who were administered nucleoside analogues and maintained virological response for ≥ 6 mo [hepatitis B virus (HBV) DNA seroconversion] before cessation of treatment were enrolled between February 2007 and January 2010. The criteria for the cessation of the antiviral treatment were defined as follows:(1) achievement of virological response; and (2) duration of consolidation therapy (≥ 6 mo). After treatment cessation, the patients were followed up at 3-6 mo intervals. The primary endpoint was serologic and virologic recurrence rates after withdrawal of antiviral treatment. Serologic recurrence was defined as reappearance of HBeAg positivity after HBeAg seroconversion. Virologic recurrence was defined as an increase in HBV-DNA level > 104 copies/mL after HBeAg seroconversion with previously undetectable HBV-DNA level. RESULTS:During the median follow-up period of 18.2 mo (range:5.1-47.5 mo) after cessation of antiviral treatment, the cumulative serological recurrence rate was 15 % at 12 mo. The median duration between the cessation of antiviral treatment and serologic recurrence was 7.2 mo (range:1.2-10.9 mo). Of the 48 patients with HBeAg positive chronic hepatitis, 20 (41.6%) showed virological recurrence. The cumulative virologic recurrence rates at 12 mo after discontinuing the antiviral agent were 41%. The median duration between off-treatment and virologic recurrence was 7.6 mo (range:4.3-27.1 mo). The mean age of the virological recurrence group was older than that of the non-recurrence group (46.7 ± 12.1 years vs 38.8 ± 12.7 years, respectively; P = 0.022). Age (> 40 years) and the duration of consolidation treatment (≥ 15 mo) were significant predictive factors for offtreatment durability in the multivariate analysis [P = 0.049, re

关键词： Durability seroconversion Chronic hepatitis B Hepatitis B e antigen positive Recurrence Consolidation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

引用

Science China(Life Sciences) 2020年第12期63卷 1833-1849页

作者： Ligong Lu Hui Zhang Meixiao Zhan Jun Jiang Hua Yin Danielle JDauphars Shi-You Li Yong Li You-Wen He Zhuhai Interventional Medical Center Zhuhai Precision Medical CenterZhuhai People's HospitalZhuhai Hospital Affiliated with Jinan UniversityZhuhai 519000China First Affiliated Hospital China Medical UniversityShenyang 110001China tricision Biotherapeutic Inc. Zhuhai 519041China Department of Immunology Duke University Medical University Medical CenterDurhamNC 27710USA

The newly emerged severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019(COVID-19) due to SARSCoV-2 infection is lacking, and different therapeutic strategies are under testing. Host humoral and cellular immunity to SARSCoV-2 infection is a critical determinant for patients’ outcomes. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement. Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients, including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies and early clinical testing, as well as clinical results from several COVID-19 vaccine candidates. In this review, we summarize the recent progress and discuss the implications of these findings in vaccine development.

关键词： COVID-19 seroconversion neutralizing antibody spike protein SARS-CoV-2 convalescent plasma vaccine

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen≤1500 IU/mL:An observational study

引用

World Journal of Gastroenterology 2020年第13期26卷 1525-1539页

作者： Feng-Ping Wu Ying Yang Mei Li Yi-Xin Liu Ya-Ping Li Wen-Jun Wang Juan-Juan Shi Xin Zhang Xiao-Li Jia Shuang-Suo Dang Department of Infectious Diseases the Second Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 710004Shaanxi ProvinceChina

BACKGROUND Nucleos(t)ide analog(NA)has shown limited effectiveness against hepatitis B surface antigen(HBsAg)clearance in chronic hepatitis B(CHB)*** To evaluate the efficacy and safety of add-on peginterferonα-2a(peg-IFNα-2a)to an ongoing NA regimen in CHB *** In this observational study,195 CHB patients with HBsAg≤1500 IU/m L,hepatitis B e antigen(HBeAg)-negative(including HBeAg-negative patients or HBeAg-positive patients who achieved HBeAg-negative after antiviral treatment with NA)and hepatitis B virus-deoxyribonucleic acidseroconversion rate in the add-on group was 29.7%(27/91)at week 72,and no patient in the monotherapy group achieved HBsAg seroconversion at week *** HBsAg clearance and seroconversion rates in the add-on group were significantly higher than in the monotherapy group at week 72(P<0.001).Younger patients,lower baseline HBsAg concentration,lower HBsAg concentrations at weeks 12 and 24,greater HBsAg decline from baseline to weeks 12 and 24 and the alanine aminotransferase≥2×upper limit of normal during the first 12 wk of therapy were st

关键词： Chronic hepatitis B Peginterferonα-2a Nucleos(t)ide analog Hepatitis B surface antigen clearance Hepatitis B surface antigen seroconversion Add-on therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients

引用

World Journal of Gastroenterology 2010年第43期16卷 5447-5451页

作者： Sylvia Brost Paul Schnitzler Wolfgang Stremmel Christoph Eisenbach Department of Gastroenterology and Infectious Diseases University of Heidelberg Department of Infectious Diseases Virology University of Heidelberg

AIM: To study the efficacy and safety of entecavir (ETV) as first-line therapy for hepatitis B virus (HBV) reactivation due to immunosuppression. METHODS: Four patients that were treated with different immunosuppressive regimens for hematological malignancies, who presented with HBV reactivation were treated with ETV. Clinical outcome, biochemical and virological factors, including quantitative hepatitis B surface antigen (HBsAg) were studied. RESULTS: In all patients, ETV induced suppression of HBV, and rapid clinical improvement without side effects. In one patient with an alanine aminotransferase (ALT) flare, tenofovir was added after 3 mo of treatment. Until death from disease progression at 6 mo after treatment initiation, this patient did not clear HBV infection. Retrospectively, it is highly probable that thepatient had been non-adherent. In the other three patients, the virological responses were associated with an expeditious decrease in quantitative HBsAg titers with negativity after 2 mo, and all three had HBsAg seroconversion. In one patient, HBV DNA reached a plateau after 3 mo, before becoming undetectable after 1 year, despite early ALT normalization and undetectable quantitative HBsAg. CONCLUSION: ETV seems to be effective and safe treatment for HBV reactivation. Monitoring of quantitative HBsAg might be an additional useful tool to monitor treatment response.

关键词： Hepatitis B virus Entecavir Immunosuppression Hepatitis B surface antigen seroconversion

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Clinical features of HBs Ag seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study

引用

World Journal of Gastroenterology 2016年第44期22卷 9836-9843页

作者： Young Min Park Seong Gyu Lee Hepatology Center Department of Internal Medicine and Biomedical Research Center Bundang Jesaeng General Hospital epartment of Laboratory Medicine Bundang Jesaeng General Hospital

AIM To investigate the characteristic features of hepatitis B surface antigen(HBs Ag) seroclearance among Korean hepatitis B virus(HBV) *** Carriers with HBs Ag seroclearance were selected by analyzing longitudinal data collected from 2003 to 2015. The period of time from enrollment to the negative conversion of HBs Ag(HBs Ag-NC) was compared by stratifying various factors, including age, sex, hepatitis B e antigen(HBe Ag), HBV DNA, sequential changes in the signal-to-cutoff ratio of HBs Ag(HBs Ag-SCR), as measured by qualitative HBs Ag assay, and chronic liver disease on ultrasonography(US-CLD). Quantification of HBV DNA and HBs Ag(HBs Ag-QNT) in the serum was performed by commercial *** Among the 1919 carriers, 90(4.7%) exhibited HBs AgNC at 6.2 ± 3.6 years after registration, with no differences observed among the different age groups. Among these carriers, the percentages of those with asymptomatic liver cirrhosis(LC) and hepatocellular carcinoma(HCC) at registration were 31% and 7.8%, respectively. The frequency of HBs Ag-NC significantly differed according to the HBV DNA titer and US-CLD. HBe Ag influenced HBs Ag-NC in the 40-50 and 50-60 year age groups. HBs Ag-SCR < 1000 was correlated with an HBs Ag-QNT < 200 IU/m L. A gradual decrease in the HBs Ag-SCR to < 1000 predicted HBs Ag-NC. Six patients developed HCC after registration, including two before and four after HBs Ag-NC. The rate at which the patients developed new HCC after HBs Ag seroclearance was 4.8%. LC with excessive drinking and vertical infection were found to be risk factors for HCC in the HBs Ag-NC *** HCC surveillance should be continued after HBs Ag seroclearance. An HBs Ag-SCR < 1000 and its decrease in sequential testing are worth noting as predictive markers of HBs Ag loss.

关键词： Hepatocellular carcinoma Hepatitis B virus Hepatitis B Surface antigen HBs Ag seroconversion Hepatitis B e antigen HBe Ag Liver cirrhosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cohort Study of HIV Infection among Drug Users in Ruili,Longchuan and Luxi of Yunnan Province,China

引用

Biomedical and Environmental Sciences 1993年第4期6卷 348-351页

作者： ZHENGXI－WEN ZHANGJIA－PENG 等 InstituteofEpidemiologyandMicrobiology ChineseAcademyofPreventiveMedicineBeijing102206China Sanitar

In March 1992, KAP investigation and HIV blood test were carried out for 860 drug users and 82 spouses in Ruili, Luxi, Longchuan of Yunnan Province, China.The results showed that there were 285 injecting drug users (IDUs) (33.1%) among 860 drug users. Among 282 blood samples of IDUs, the HIV infection rate was 49.0%, highest in Ruili (81.8%, 63/77), then Longchuan (44.6%, 74/166), lowest in Luxi county (5.1 %, 2/39). Twelve new HIV ( +) were found from 75 persons, who had been tested as HIV (-) in recent two years. Sixty-two blood samples were collected among 82 spouses of IDUs with HI V ( + ), and 6 were HIV ( + ) (9.8%), with an increase of 6.7% compared with results of the investigation two years ago (3.1%, 2/64).

关键词： Asia Behavior Biology China Developing Countries Diseases Drug Usage Eastern Asia Follow-up Studies Hiv Infections Immunity Incidence Iv Drug Users Measurement Physiology Research Report seroconversion Studies Viral Diseases

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy of intramuscular matrine in the treatment of chronic hepatitis B

引用

Hepatobiliary & Pancreatic Diseases International 2004年第1期3卷 69-72页

作者： Yao Long, Xiao-Tian Lin, Kun-Lun Zeng and Lian Zhang Zhanjiang, China Department of Infectious Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China Haibin Centre Hospital, Zhanjiang 524005, China Centre of Hepatology of Nanfang Hospital, First Military Medical University, Guang- zhou 510515, China Department of Infectious Diseases Affiliated Hospital of Guangdong Medical College Zhanjiang 524001 China. zjlongyao@***

BACKGROUND: Hepatitis B virus (HBV) infection, a glo- bal public health problem, is the leading cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide. There are more than 350 million HBV carriers in the world and up to one million die annually due to hepatitis B associated liv- er disease. So far no optimal treatment is available for pa- tients with chronic hepatitis B. In the paper we investigated the efficacy of intramuscular matrine in the treatment of chronic hepatitis B. METHODS: One hundred and twenty patients with chronic hepatitis B were randomly divided into matrine treatment group (n =60) and control group (n =60). The patients of the matrine group were given intramuscularly with matrine (an alkaloid extracted from a traditional Chinese herb Radix Sophorae Flavescentis by Guangzhou Ming Xing Pharmaceu cal Factory, Guangzhou, China) of 100 mg daily for 90 days in addition to conventional liver-protective drugs in- cluding glucurone, inosine, compound vitamin B and caryophyllin. The control group received conventional liv- er-protective drugs alone. Clinical manifestations and labo- ratory parameters including liver biochemistry and serum hepatitis B virus markers were monitored before and after treatment in the two groups. RESULTS: Significant differences were seen between the two groups in terms of improvement of clinical symptoms and signs, recovery of liver functions, and serum conver- sion from hepatitis Be antigen to HBe antibody and from positive to negative serum HBV DNA (P <0.05-0.01). The result of the matrine group was more marked than that of the control group. Serious side-effects were not observed except mild pain at the site of injection of matrine in a few patients. CONCLUSION: These results indicate that intramuscular matrine may be an economical, efficacious, safe drug for the treatment of chronic hepatitis B.

关键词： chronic hepatitis B/therapy matrine/therapeutical effect HBV DNA hepatitis B surface antigen hepatitis Be antigen seroconversion

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Chronic hepatitis B in children with or without malignancies:A 13-year follow-up

引用

World Journal of Gastroenterology 2015年第7期21卷 2073-2079页

作者： Merve Usta Nafiye Urganci Zeynep Yildiz Yildlrmak Sema Dogan Vural Department of Pediatric Gastroen-terology Sisli Hamidiye Etfal Education and Research Hospital Department of Pediatric Haematology Sisli Hamidiye Etfal Education and Research Hospital Department of Pediatric Oncology Sisli Hamidiye Etfal Education and Research Hospital

AIM:To evaluate the outcome of chronic hepatitis B(CHB)in children with or without ***:Twenty four children(15 boys and 9 girls)with malignancies,followed up by the pediatric gastroenterology outpatient clinic for CHB between January 2000 and December 2013,were enrolled in the study(Group 1).Group 2 was formed with twenty five children(11 girls and14 boys)diagnosed with CHB without *** data from the patients’records were compared between the two ***:Hepatitis B e antigen(HBe Ag)/anti HBe seroconversion was observed in 3 patients(12.5%)in group 1 and 15 patients(60%)in group 2,with annual seroconversion rates of 1.61%and 16.6%,respectively,and the difference was significant(Pseroconversion after treatment and the difference between the two groups was significant(Pseroconversion rate was lower in patients who had recovered from cancer.

关键词： Chronic hepatitis B Children Pediatric malignancies seroconversion Course of the disease

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Protection Efficacy of Recombinant Infectious Laryngotracheitis Vaccine in Chicks

引用

Journal of Agricultural Science and Technology(A) 2011年第8期1卷 1112-1114页

作者： K. Chumpolbanchorn P. Anankeatikul R. Thampisarn S. Jittakhot S. Leethochawalit Faculty of Veterinary Science Mahidol University Salaya Phuttamonthon Nakhon Pathom 73170 Thailand CEVA Animal Health （Thailand） Ltd Bangkok 10400 Thailand

A commercial recombinant fowl pox vectored infectious laryngotracheitis （ILT） vaccine was examined its protection efficacy in one-day-old chicks by subcutaneous route with various dose-strength. The treatment groups I-III birds were vaccinated with a full, 1/2 and 1/3 dose of recommendation dose, respectively. Thereafter, at 6 wk post vaccination, they were challenged with 5x labeled dose of live ILT vaccine. Protection efficacy of the vaccine was compared among groups based on antibody production and eye lesion score. The results of eye lesion score showed that there was a significant difference between control and treatment groups, whereas the difference was not found among the treatment groups. For seroconversion, there was no significant difference between birds in group I and II. However, higher number of seroconversion birds in groups I and II than group III was observed （P 〈 0.05）. It was concluded that a half dose of recommendation dose had the same protection efficacy as a full dose of recombinant YP-LT vaccine.

关键词： Recombinant vaccine infectious laryngotracheitis fowl pox vectored seroconversion eye lesion score

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

卡介苗接种效果影响因素分析及护理

引用

吉林医学 2013年第31期34卷 6570-6571页

作者：孔香兰杨德云熊永红新疆医科大学第五附属医院预防保健科新疆830011

目的：了解影响新生儿卡介苗接种的因素,以提高卡介苗的接种效果。方法：对2010年10月~2011年6月接种卡介苗的婴幼儿（由于各种原因在出生时未及时接种卡介苗）210例进行追踪观察。结果：210例婴幼儿卡介苗接种后PPD试验阳转率为57.6%,... 详细信息

目的：了解影响新生儿卡介苗接种的因素,以提高卡介苗的接种效果。方法：对2010年10月~2011年6月接种卡介苗的婴幼儿（由于各种原因在出生时未及时接种卡介苗）210例进行追踪观察。结果：210例婴幼儿卡介苗接种后PPD试验阳转率为57.6%,接种时药液无外漏,皮丘标准,卡痕明显者PPD试验阳转率高。结论：卡介苗接种后PPD试验阳转率与有效卡痕有关。

关键词： Newborn BCG seroconversion

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：